Acquired entity Ology Bioservices was acquired by National Resilience, Inc. in 2021, indicating integration into a larger biomanufacturing platform with expanded capabilities and customer access. This suggests cross-sell opportunities for Resilience’s broader contract manufacturing, development, and platform services to former Ology clients and ongoing programs.

DoD legacy Historically engaged with U.S. government contracts, including a major 10-year, $400M+ DoD MCM ADM contract and a BSL-3 facility, signaling a track record in defense-facing biosafety, regulatory compliance, and large-scale manufacturing that appeals to government and defense-related customers seeking proven partners.

Biologics focus Proprietary platform technologies for producing biologics such as proteins, monoclonal antibodies, and vaccines point to opportunities to offer development, formulation optimization, and cGMP manufacturing services to biotech firms pursuing biologics pipelines, especially those needing scalable production capacity.

Growing platform Resilience’ expansion and investment activity, including $100M facility development in Blue Ash and strategic partnerships in AI-driven drug discovery, indicate a growing ecosystem. This creates cross-sell paths for Ology’s manufacturing and development services alongside Resilience’s broader tech-enabled biomanufacturing solutions.

Mid-market focus Ology operates with 11-50 employees and revenue in the 10M-25M range, positioning it as a mid-market partner. This creates sales opportunities to engage midsize biotech firms seeking flexible, scalable, and cost-effective GMP capabilities and development support.